Results 31 to 40 of about 144,610 (311)

Neoadjuvant Therapy for Primary Resectable Retroperitoneal Sarcomas—Looking Forward

, 2022
The cornerstone of therapy for primary retroperitoneal sarcomas (RPS) is complete surgical resection, best achieved by resecting the tumor en bloc with adherent structures even if not overtly infiltrated.
Alexandra C. Istl, Alessandro Gronchi
core   +1 more source

Neoadjuvant treatment for resectable pancreatic adenocarcinoma: What is the best protocol?

Annals of Gastroenterological Surgery, 2020
Although upfront surgery has been the gold standard for pancreatic adenocarcinoma that is planned for resection, it should be compared with the alternative strategy of neoadjuvant therapy.
Fuyuhiko Motoi, Michiaki Unno
doaj   +1 more source

Ifosfamide with regional hyperthermia in soft-tissue sarcomas [PDF]

, 2003
For high-risk soft tissue sarcomas (HR-STS) of adults, new treatment strategies are needed to improve outcome with regard to local control and overall survival.
M. Schlemmer, Wendtner, Clemens-Martin, C.M. Wendtner, R.D. Issels, Schlemmer, M., Issels, Rolf-Dieter   +5 more
core   +1 more source

Role for Neoadjuvant Systemic Therapy for Potentially Resectable Pancreatic Cancer

, 2023
Despite aggressive adjuvant management, a high percentage of patients who undergo appropriate surgical resection for pancreatic cancer will see their cancer recur and thus will not be cured. An important paradigm shift to achieve better outcomes has been
Brandon G. Smaglo
core   +1 more source

Post-Neoadjuvant Treatment Strategies in Breast Cancer

, 2022
Neoadjuvant chemotherapy enables close monitoring of tumor response in patients with breast cancer. Being able to assess tumor response during treatment provides an opportunity to evaluate new therapeutic strategies.
Bálint Tamaskovics, Markus Dommach, Danny Jazmati, Svjetlana Mohrmann, Tanja Fehm, Eugen Ruckhäberle, Carolin Nestle Krämling, David Krug, Christiane Matuschek, Edwin Bölke, Jan Haussmann, Stefanie Corradini, Wilfried Budach   +12 more
core   +1 more source

The Role of VEGFA, COX2, HUR and CUGBP2 in Predicting the Response to Neoadjuvant Therapy in Rectal Cancer Patients

Medicina, 2020
Background and objectives: The effectiveness of neoadjuvant therapy, which is commonly used for stage II-III rectal cancer (RC) treatment, is limited. Genes associated with the pathogenesis of RC could determine response to this treatment. Therefore, the
Henrikas Pauzas, Ugne Gyvyte, Tadas Latkauskas, Laura Kairevice, Paulius Lizdenis, Saulius Svagzdys, Erika Birgiolaite, Irma Kuliaviene, Juozas Kupcinskas, Algimantas Tamelis   +9 more
doaj   +1 more source

Visual analysis of the research hotspots in neoadjuvant therapy for patients with gastric cancer

Frontiers in Gastroenterology, 2023
ObjectiveThis study aimed to analyze the research hotspots and frontiers in the field of neoadjuvant therapy for patients with gastric cancer (GC) using bibliometric and identify its developmental trends.MethodsThe literature related to neoadjuvant ...
Tianxing Chen, Tianxing Chen, Yating Liu, Yating Liu, Jing Gao, Dekui Zhang, Dekui Zhang   +6 more
doaj   +1 more source

Comparison of Standard Neoadjuvant Therapy and Total Neoadjuvant Therapy in Terms of Effectiveness in Patients Diagnosed with Locally Advanced Rectal Cancer

Medicina
Background/Objectives: The study aimed to compare the treatment effectiveness of patients with locally advanced rectal cancer undergoing standard neoadjuvant therapy or total neoadjuvant therapy.
Ayberk Bayramgil, Ahmet Bilici, Ali Murat Tatlı, Seda Kahraman, Yunus Emre Altintas, Fahri Akgul, Musa Barış Aykan, Jamshid Hamdard, Sema Sezgin Göksu, Mehmet Ali Nahit Şendur, Fatih Selçukbiricik, Ömer Fatih Ölmez   +11 more
doaj   +1 more source

Peripheral T lymphocyte and immunocyte subset dynamics: markers of neoadjuvant therapy outcomes in esophageal squamous cell carcinoma

Frontiers in Immunology, 2023
PurposeIn patients with resectable esophageal squamous cell carcinoma (ESCC), neoadjuvant therapy increased the curative resection rate, disease-free survival, and overall survival for patients with resectable ESCC.
Xin Nie, Shuya He, Xinming Nie, Changding Li, Kunyi Du, Wenwu He, Zhiyu Li, Kunhan Ni, Simiao Lu, Chenghao Wang, Kangning Wang, Yan Miao, Longlin Jiang, Jiahua Lv, Guangyuan Liu, Qiang Fang, Lin Peng, Wenguang Xiao, Qifeng Wang, Dongsheng Wang, Yongtao Han, Xuefeng Leng   +21 more
doaj   +1 more source

Neoadjuvant Therapy for Rectal Cancer [PDF]

Diseases of the Colon & Rectum, 2018
A 63-year-old man presents to his primary care doctor with a one-month history of blood in his stools. He is referred for a colonoscopy and found to have a friable mass along the anterior wall just proximal to the second rectal fold. A biopsy confirms moderately-differentiated adenocarcinoma.
Ira L, Leeds, Sandy H, Fang
openaire   +2 more sources